North America Blood Plasma Derivatives Market

The North America blood plasma derivatives market was valued at US$ 11,821.24 million in 2022 and is projected to reach US$ 20,447.70 million by 2028; it is expected to grow at a CAGR of 9.6% from 2022 to 2028.

Increase in Prevalence of Blood Disorders is Driving the North America Blood Plasma Derivatives Market

According to the National Organizations of Rare Disorders, hemophilia A is a common X-linked recessive disorder and the second most common inherited clotting factor deficiency after von Willebrand disease. According to the National Library of Medicine (NLM), ~30,000–33,000 males were affected by hemophilia in the US in 2020. In the US, ~1 in 5,000 newborn males suffers from hemophilia A. According to National Organization for Rare Disorders, in 2022, immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affects ~66 adults per 1 million in the US. Moreover, in the country, the incidence of ITP in adults is ~3.3 per 100,000/year, while the prevalence is 9.5 per 100,000. Furthermore, according to the US Department of Health & Human Services, in 2020, ~100,000 Americans had sickle cell disease (SCD), the most inherited blood disorder. Furthermore, by 2050, the number of SCD cases is expected to grow by ~30%. Hence, Plasma is a liquid portion of blood containing WBC and platelets. Blood plasma derivatives play a major role in stopping bleeding after an injury. Thus, the increasing prevalence of blood disorders across the world is one of the major driving factors promoting the growth of the blood plasma derivatives market growth.  

North America Blood Plasma Derivatives Market Overview  

The North America blood plasma derivatives market has been segmented into the US, Canada, and Mexico. US is expected to account for the largest market share. The prevalence of severe diseases, including hemophilia and immune deficiency disorders, is a main factor driving the market for blood plasma derivatives. According to the Centers for Disease Control and Prevention (CDC) data, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. The exact number of people living with hemophilia in the US is unknown. Based on a recent study that used data collected on patients receiving care in federally funded hemophilia treatment centers during the period 2012-2018, as many as 33,000 males in the US are living with the disorder.

Furthermore, as per World Health Organization (WHO), out of 250,000 individuals diagnosed with PID (primary immune deficiencies) in the US in 2017, roughly 125,000 get month-to-month mixtures of immunoglobulins. It is assessed that more than 300,000 patients get monthly-to-month immunoglobulins implantations for PID. The rise in chronic conditions and increasing demand for immunoglobulin drive the development of the blood plasma derivatives market.

North America Blood plasma derivatives Market Revenue and Forecast to 2028 (US$ Million)

North America Blood Plasma Derivatives Strategic Insights

Strategic insights for the North America Blood Plasma Derivatives provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Blood Plasma Derivatives Report Scope

North America Blood Plasma Derivatives Regional Insights

The geographic scope of the North America Blood Plasma Derivatives refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

North America Blood plasma derivatives Market Segmentation

The North America blood plasma derivatives market is segmented into type, application, end user, and country.

The North America blood plasma derivatives market, by type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held a larger market share in 2022.   

Based on application, the North America blood plasma derivatives market is divided into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The immunodeficiency diseases applications segment held the largest share of the market in 2022.

The blood plasma derivatives market, by end user, is segmented into hospitals, diagnostic laboratories, clinics, and other end users. The hospitals segment held the largest share of the market in 2022.  

Based on country, the North America blood plasma derivatives market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.

Grifols SA; SK Plasma Co Ltd; Octapharma AG; Monobind Inc.; Intas Pharmaceuticals Ltd; Takeda Pharmaceutical Co Ltd; CSL Behring LLC; LFB SA; and Kedrion SpA are the leading companies operating in the North America blood plasma derivatives market.